In patients with biochemical recurrence after primary radiotherapy for prostate cancer, both the 5-point PRIMARY and E-PSMA Likert scoring systems score demonstrated good performance and substantial interreader agreement between experts for detection of intraprostatic recurrences. This evidence concerns the gene FOLH1 and prostate carcinoma.